Navigation Links
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Date:10/7/2008

allel-group, four-week study with dose escalations in 414 adults aged 18 to 55 years, adults with ADHD experienced significant improvements in ADHD symptoms within one week of treatment with once-daily VYVANSE.

Treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo, with a mean reduction in ADHD Rating Scale (ADHD-RS-IV) scores (16.2 to 18.6 points; P<.0001); demonstrating a 40 to 45 percent decrease at endpoint. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing response to treatment. The scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision(R), a publication of the American Psychiatric Association.

Investigators also measured the efficacy of VYVANSE using the Clinical Global Impressions-Improvement (CGI-I) scale. On this scale, the percentage of adults taking VYVANSE rated by investigators as "much improved" or "very much improved" ranged from 57 to 61 percent at endpoint and was significantly greater than placebo (P<.01). The CGI-I is a standard assessment used to rate a patient's improvement over time.

The most common adverse events in the study were decreased appetite, difficulty falling asleep, and dry mouth.

"This study was one of the largest controlled stimulant trials in adults with ADHD, and these data reinforce the importance of VYVANSE as a new once-daily treatment option for adults with ADHD that significantly improved their ADHD symptoms," said Mike Cola, President of Shire's Specialty Pharmaceuticals business. "Shire recognizes the need for more research on ADHD in the adult population and is committed to advancing the science of ADHD and providing treatments that help children and adults diagnosed with ADHD to lead more productive lives."

VYVANSE is a therapeutically inactive prodrug, in which d-
'/>"/>

SOURCE Shire Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)...  With the heroin epidemic in the ... Jacksonville -based Lakeview Health drug and alcohol treatment ... explain why fentanyl is causing a new wave of ... more potent than pharmaceutical grade heroin and often illegally ... of death skyrockets. "Fentanyl can be an ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
(Date:8/28/2015)... ... ... Rio Salado College joined nine educational institutions in Washington D.C., July ... - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the Bill ... hosted by EDUCAUSE and NGLC, which is designed to bring leadership teams of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... ... alcohol abuse, or those who might personally be struggling with chemical dependency, may ... post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Harbor Laboratory (CSHL) has demonstrated for the first time ... can initiate signaling that regulates both the structure and ... suggests a significant role for this class of receptors ... but also in cognition and in pathological processes in ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... Controlling heart rate is key when heart failure, irregular ... News) -- When added to heart failure, the irregular ... , Now, an international study shows that a ... best first option for keeping patients healthy under these ...
... HILL, N.C., June 18 A CI head once ... have it, but the only,time you realize you need ... In today,s marketing space, most companies need competitive,intelligence to ... the key insights are lacking that people begin to ...
... Prevent Skin Cancer, HOUSTON, June 18 Now that ... us, the cancer care experts at Texas Oncology remind,Texans to ... Although the most prevalent cancer in the United States today,skin ... more than 1,million annual U.S. cases of skin cancer are ...
... List from a ... Worldwide Field of 5,000, PHILADELPHIA, June ... of SCA Personal Care, from among,5,000 companies for inclusion in its ... think-tank dedicated to the research and,promotion of profitable best practices in ...
Cached Medicine News:Health News:Neuroscientists show insulin receptor signaling regulates structure of brain circuits 2Health News:Neuroscientists show insulin receptor signaling regulates structure of brain circuits 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2Health News:Texas Oncology Urges Texans to 'Save Your Skin' 2Health News:Texas Oncology Urges Texans to 'Save Your Skin' 3Health News:Ethisphere Institute Names SCA to List of Top Ethical Companies 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
Medicine Products: